Detection of breast carcinoma with an ICG enhanced optical imaging device in breast cancer patients.
Completed
- Conditions
- breast cancerlumpectomy1000629110006295
- Registration Number
- NL-OMON33137
- Lead Sponsor
- niversitair Medisch Centrum Groningen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 10
Inclusion Criteria
Women above the age of 21 who have biopsy-proven breast cancer stage I-II who are undergoing lumpectomy
Exclusion Criteria
Pregnant women, significant renal, cardiac or pulmonary disease, history of iodine allergy or anaphylactic reactinos to insect bites or medication, presence or history of hyperthyroidism
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Primary Objective:<br /><br>* Ergonomics and function of the imaging system - the NIRF imaging system<br /><br>should not interfere with the standard lumpectomy procedure and be used safely<br /><br>by the surgeon while detection of ICG takes place. Duration: 1,5 hour clinical<br /><br>procedure </p><br>
- Secondary Outcome Measures
Name Time Method <p>none</p><br>